Journal of Medicinal Chemistry
Brief Article
(13) Robey, R. W.; Steadman, K.; Polgar, O.; Morisaki, K.;
Blayney, M.; Mistry, P.; Bates, S. E. Pheophorbide a is a specific
probe for ABCG2 function and inhibition. Cancer Res. 2004, 64,
1242−1246.
for rereading the manuscript and improving the English. G.V.
was the recipient of a mobility fellowship from the Brazilian
CAPES (Process number 2303/10-8). E.G.-B. and C.G. were
́ ̂
recipients of doctoral fellowships from the Region Rhone-Alpes
(14) Kuhnle, M.; Egger, M.; Muller, C.; Mahringer, A.; Bernhardt, G.;
̈
and the Ligue Nationale Contre le Cancer, respectively.
Financial support was provided by the CNRS and Universite
Lyon 1 (UMR 5086), the Ligue Nationale Contre le Cancer
Fricker, G.; Konig, B.; Buschauer, A. Potent and selective inhibitors
of breast cancer resistance protein (ABCG2) derived from the
p-glycoprotein (ABCB1) modulator tariquidar. J. Med. Chem. 2009, 52,
1190−1197.
́
́
́ ̂
(Equipe labellisee Ligue 2011), the Region Rhone-Alpes
(CIBLE 2010), and an international grant from French ANR
and Hungarian NIH (2010-INT-1101-01).
(15) Pick, A.; Muller, H.; Wiese, M. Novel lead for potent inhibitors
̈
of breast cancer resistance protein (BCRP). Bioorg. Med. Chem. Lett.
2010, 20, 180−183.
(16) Boumendjel, A.; Macalou, S.; Ahmed-Belkacem, A.; Blanc, M.;
Di Pietro, A. Acridone derivatives: design, synthesis, and inhibition of
breast cancer resistance protein ABCG2. Bioorg. Med. Chem. 2007, 15,
2892−2897.
ABBREVIATIONS USED
■
ABC, ATP-binding cassette; MDR, multidrug resistance;
MRP1, multidrug resistance protein 1; MTT, 3-(4,5-dime-
thylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide
̀
(17) Arnaud, O.; Boumendjel, A.; Geze, A.; Honorat, M.; Matera, E. L.;
Guitton, J.; Stein, W. D.; Bates, S. E.; Falson, P.; Dumontet, C.; Di Pietro,
A.; Payen, L. The acridone derivative MBLI-87 sensitizes breast cancer
resistance protein-expressing xenografts to irinotecan. Eur. J. Cancer
2011, 47, 640−648.
REFERENCES
■
(1) Endicott, J. A.; Ling, V. The biochemistry of P-glycoprotein-
mediated multidrug-resistance. Annu. Rev. Biochem. 1989, 58, 137−
171.
(2) Gottesman, M. M.; Pastan, I. Biochemistry of multidrug
resistance mediated by the multidrug transporter. Annu. Rev. Biochem.
1993, 62, 385−427.
(3) Cole, S. P. C.; Bhardwaj, G.; Gerlach, J. H.; Mackie, J. E.; Grant,
C. E.; Almquist, K. C.; Stewart, A. J.; Kurz, E. U.; Duncan, A. M. V.;
Deeley, R. G. Overexpression of a transporter gene in a multidrug-
resistant human lung cancer cell line. Science 1993, 258, 1650−1654.
(4) Allikmets, R.; Schriml, L. M.; Hutchinson, A.; Romano-Spica, V.;
Dean, M. A human placenta-specific ATP-binding cassette gene
(ABCP) on chromosome 4q22 that is involved in multidrug resistance.
Cancer Res. 1998, 58, 5337−5339.
(5) Doyle, L. A.; Yang, W.; Abruzzo, L. V.; Krogmann, T.; Gao, Y.;
Rishi, A. K.; Ross, D. D. A multidrug resistance transporter from
human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. U.S.A. 1998, 95,
15665−15670.
(6) Miyake, K.; Mickley, L.; Litman, T.; Zhan, Z.; Robey, R.;
Cristensen, B.; Brangi, M.; Greenberger, L.; Dean, M.; Fojo, T.; Bates,
S. E. Molecular cloning of cDNAs which are highly overexpressed in
mitoxantrone-resistant cells: demonstration of homology to ABC
transport genes. Cancer Res. 1999, 59, 8−13.
(7) Ahmed-Belkacem, A.; Pozza, A.; Macalou, S.; Perez-Victoria, J. M.;
Di Pietro, A. Inhibitors of cancer cell multidrug resistance mediated by
breast cancer resistance protein (BCRP/ABCG2). Anticancer Drugs
2006, 17, 239−243.
(8) Boumendjel, A.; Macalou, S.; Valdameri, G.; Pozza, A.; Gauthier,
C.; Arnaud, O.; Nicolle, E.; Magnard, S.; Falson, P.; Terreux, R.;
Carrupt, P.-A.; Payen, L.; Di Pietro, A. Targeting the multidrug
ABCG2 transporter with flavonoidic inhibitors: In vitro optimization
and in vivo validation. Curr. Med. Chem. 2011, 18, 3387−3401.
(9) Rabindran, S. K.; He, H.; Singh, M.; Brown, E.; Collins, K. I.;
Annable, T.; Greenberger, L. M. Reversal of a novel multidrug
resistance mechanism in human colon carcinoma cells by fumitre-
morgin C. Cancer Res. 1998, 58, 5850−5858.
(10) van Loevezijn, A.; Allen, J. D.; Schinkel, A. H.; Koomen, G. J.
Inhibition of BCRP-mediated drug efflux by fumitremorgin-type
indolyl diketopiperazines. Bioorg. Med. Chem. Lett. 2001, 11,
29−32.
(18) Boumendjel, A.; Nicolle, E.; Moraux, T.; Gerby, B.; Blanc, M.;
Ronot, X.; Boutonnat, J. Piperazinobenzopyranones and phenalkyl-
aminobenzopyranones: potent inhibitors of breast cancer resistance
protein (ABCG2). J. Med. Chem. 2005, 48, 7275−7281.
(19) Hadjeri, M.; Barbier, M.; Ronot, X.; Mariotte, A.-M.;
Boumendjel, A.; Boutonnat, J. Modulation of P-glycoprotein-mediated
multidrug resistance by flavonoid derivatives and analogues. J. Med.
Chem. 2003, 46, 2125−2131.
(20) Ahmed-Belkacem, A.; Pozza, A.; Munoz-Martinez, F.; Bates,
S. E.; Castanys, S.; Gamarro, F.; Di Pietro, A.; Perez-Victoria, J. M.
́
Flavonoid structure-activity studies identify 6-prenylchrysin and
tectochrysin as potent and specific inhibitors of breast cancer
resistance protein ABCG2. Cancer Res. 2005, 65, 4852−4860.
(21) Macalou, S.; Ahmed-Belkacem, A.; Borelli, F.; Capasso, R.;
Fattorusso, E.; Taglialatela-Scafati, O.; Di Pietro, A. Non-prenylated
rotenoids, a new class of potent breast cancer resistance protein
inhibitors. J. Med. Chem. 2007, 50, 1933−1938.
(22) Nicolle, E.; Boccard, J.; Guilet, D.; Dijoux, M.-G.; Zelefac, F.;
Macalou, S.; Grosselin, J.; Schmidt, J.; Carrupt, P.-A.; Di Pietro, A.;
Boumendjel, A. Breast cancer resistance protein (BCRP/ABCG2):
New inhibitors and QSAR studies by a 3D linear solvation-energy
approach. Eur. J. Pharm. Sci. 2009, 38, 39−46.
(23) Nicolle, E.; Boumendjel, A.; Macalou, S.; Genoux, E.; Ahmed-
Belkacem, A.; Carrupt, P.-A.; Di Pietro, A. QSAR analysis and
molecular modeling of ABCG2-specific inhibitors. Adv. Drug Pharm.
Sci. 2009, 61, 34−46.
(24) Pick, A.; Muller, H.; Mayer, R.; Haenisch, B.; Pajeva, I. K.;
̈
Weigt, M.; Bonisch, H.; Muller, C. E.; Wiese, M. Structure-activity
̈
̈
relationships of flavonoids as inhibitors of breast cancer resistance
protein (BCRP). Bioorg. Med. Chem. 2011, 19, 2090−2102.
(25) Valdameri, G.; Pereira Rangel, L.; Sapatafora, C.; Guitton, J.;
Gauthier, C.; Arnaud, O.; Ferreira-Pereira, A.; Falson, P.; Winnischofer,
S. M. B.; Rocha, M. E. M.; Tringali, C.; Di Pietro, A. Methoxy stilbenes
as potent, specific, untransported and noncytotoxic inhibitors of breast
cancer resistance protein. ACS Chem. Biol. 2011, inpress.
(26) Burger, H.; van Tol, H.; Boersma, A. W.; Brok, M.; Wiemer, E.
A.; Stoter, G.; Nooter, K. Imatinib mesylate (STI571) is a substrate for
the breast cancer resistance protein (BCRP)/ABCG2 drug pump.
Blood 2004, 104, 2940−2942.
(27) Robey, R. W.; Honjo, Y.; van de Laar, A.; Miyake, K.; Regis,
J. T.; Litman, T.; Bates, S. E. A functional assay for detection of the
mitoxantrone resistance protein, MXR (ABCG2). Biochim. Biophys.
Acta, Biomembr. 2001, 1512, 171−182.
(28) Mosmann, T. Rapid colorimetric assay for cellular growth and
survival. Application to proliferation and cyto-toxicity assays.
J. Immunol. Methods 1983, 65, 55−63.
(11) Allen, J. D.; van Loevezijn, A.; Lakhai, J. M.; van der Valk, M.;
van Tellingen, O.; Reid, G.; Schellens, J. H. M.; Koomen, G. J.;
Schinkel, A. H. Potent and specific inhibition of the breast cancer
resistance protein multidrug transporter in vitro and in mouse
intestine by a novel analogue of fumitremorgin C. Mol. Cancer Ther.
2002, 1, 417−425.
(12) de Bruin, M.; Miyake, K.; Litman, T.; Robey, R. W.; Bates, S. E.
Reversal of resistance by GF120918 in cell lines expressing the ABC
half-transporter, MXR. Cancer Lett. 1999, 146, 117−126.
970
dx.doi.org/10.1021/jm201404w | J. Med. Chem. 2012, 55, 966−970